

[REDACTED]

Date 18 June 2026
Your Ref FOI-2026-3385
Our Ref FOI-2026-3385

Enquiries to [REDACTED]
Email psd.foi@nhs.scot

Dear [REDACTED],

Freedom of Information Reference FOI-2026-3385

I refer to your Freedom of Information (Scotland) Act 2002 (FOISA) request that we received on 04 June 2026 requesting the following information:

I refer to the information disclosed by Public Services Delivery Scotland (PSD Scotland) in response to my previous FOI request (Your Reference: FOI-2026-3348, dated 21 May 2026).

That response confirmed that PSD Scotland holds multiple active contracts with Teva UK Ltd (a subsidiary of Teva Pharmaceutical Industries Ltd), and that no contract has ever been reviewed, suspended, or terminated on ethical grounds under post-award monitoring. The response also noted the existence of Scottish Procurement Policy Note 3/2026 – (Public procurement: human rights and grave professional misconduct, published March 2026), which explicitly identifies involvement in illegal settlements as grounds for exclusion.

This follow-up request seeks specific information to determine whether SPPN 3/2026 is being implemented.

Question 1: Contract Values for Teva UK Ltd Contracts

For each of the contracts with Teva UK Ltd listed in your response to FOI-2026-3348, please provide:

**Total contract value The full agreed amount for the entire duration of the contract
Annual spend The actual spend for the most recent complete financial year (2025/2026, or the nearest 12-month period available)**

List of contract references:

NP30923, NP30925, NP33923, NP35923a, NP36123a, NP39723a, NP40923a, NP36122, NP36124, NP36126, NP36722, NP39722f, NP39724, NP39724b, NP39724g, NP39825, NP40919, NP40923, NP40925, NP41125, NP43324, NP43326, NP47822, NP47825, NP49425.

If individual contract values cannot be disclosed due to commercial sensitivity under FOISA Section 33(1)(b), please provide the aggregate annual spend across all Teva UK Ltd contracts as a minimum.

Question 2: Application of SPPN 3/2026

Please confirm:

a) Has Scottish Procurement Policy Note 3/2026 – Public procurement: human rights and grave professional misconduct – been applied to any supplier by PSD Scotland (or its predecessor NHS National Services Scotland) since its publication in March 2026?

b) If yes, please identify:

- The supplier(s) in question
- The nature of the alleged misconduct
- The outcome of the review (including any contract suspension, termination, or remedial action required)

c) If no, please state so explicitly.

Question 3: Assessment of Teva UK Ltd under SPPN 3/2026

Please confirm:

a) Has any assessment, review, or preliminary inquiry been conducted to determine whether Teva UK Ltd (or its parent company Teva Pharmaceutical Industries Ltd) is in compliance with the ethical standards required by SPPN 3/2026, specifically regarding:

- Operations in or links to illegal settlements
- Any associated human rights impacts

b) If yes, please provide a copy of any such assessment, review memorandum, or decision.

c) If no, please state the reason why no assessment has been conducted, given that PSD Scotland holds multiple contracts with this supplier and SPPN 3/2026 explicitly identifies illegal settlements as grounds for exclusion.

Question 4: Mechanism for Triggering a Supplier Review

Please describe the formal mechanism by which:

a) A member of the public; or b) An organisation, may request or trigger a review of a supplier under SPPN 3/2026.

If no such mechanism exists, please state this explicitly and advise whether PSD Scotland intends to create one.

Public Interest Statement

I submit that disclosure of the requested information is in the substantial public interest because:

- SPPN 3/2026 represents a significant Scottish Government policy commitment to ethical procurement
- The public has a right to know whether this policy is being implemented or remains dormant
- Transparency regarding public spending on suppliers linked to illegal settlements is necessary for democratic accountability

If PSD Scotland considers any part of this request exempt under FOISA, please provide a specific exemption for each withheld item and explain the public interest test applied.

We have now completed the search of our records and can provide you with the following information:

Question 1: Contract Values for Teva UK Ltd Contracts

For each of the contracts with Teva UK Ltd listed in your response to FOI-2026-3348, please provide:

Total contract value The full agreed amount for the entire duration of the contract
Annual spend The actual spend for the most recent complete financial year (2025/2026, or the nearest 12-month period available)

List of contract references:

NP30923, NP30925, NP33923, NP35923a, NP36123a, NP39723a, NP40923a, NP36122, NP36124, NP36126, NP36722, NP39722f, NP39724, NP39724b, NP39724g, NP39825, NP40919, NP40923, NP40925, NP41125, NP43324, NP43326, NP47822, NP47825, NP49425.

If individual contract values cannot be disclosed due to commercial sensitivity under FOISA Section 33(1)(b), please provide the aggregate annual spend across all Teva UK Ltd contracts as a minimum.

Question 1: Contract Values for Teva UK Ltd Contracts – Total contract value, the full agreed amount for the entire duration of the contract.

The total contract value stated for each of the above framework agreements reflects an estimated level of expenditure by NHSScotland with the appointed supplier(s). It does not constitute a guarantee or commitment by NHSScotland to spend this amount.

The total contract values for these framework agreements are published on the publicly accessible Find a Tender Service (FTS). The links provided below direct to the relevant contract award notices for each framework reference, each of which includes a breakdown of the total contract value by lot:

- NP30923: [NP30923 Psychiatry and Neurology Medicines - Find a Tender](#)
- NP30925: [NP30925 Psychiatry and Neurology Medicines - Find a Tender](#)
- NP33923: [NP33923 Ranibizumab - Find a Tender](#)
- NP35923a, NP36123a, NP39723a, NP40923a: [NP Generic Medicines Transition Tender \(October 2023\) - Find a Tender](#)
- NP36122: [Antibiotic, Antiviral & Genito Urinary Medicines - Find a Tender](#)
- NP36124: [NP36124 Antibiotic, Antiviral & Genito Urinary Medicines - Find a Tender](#)
- NP36126: [NP36126 Antibiotic & Genito Urinary Medicines - Find a Tender](#)
- NP36722: [NP36722 Fertility Products - Find a Tender](#)
- NP39722f: [NP39722f Lenalidomide - Find a Tender](#)
- NP39724: [NP39724 Generic and Biosimilar Cancer Medicines - Find a Tender](#)
- NP39724b: [NP39724b Pomalidomide and Thalidomide - Find a Tender](#)
- NP39724g: [NP39724g Plerixafor - Find a Tender](#)
- NP39825: [Gastrointestinal, Endocrine, Nutrition & Blood Medicines - Find a Tender](#)

- NP40919: [NP40919 Paracetamol 1G Solution for Infusion & Rocuronium Bromide Injection - Find a Tender](#)
- NP40925: [NP40925 Analgesics, Anaesthetics, Musculoskeletal & Joint Disease Medicines - Find a Tender](#)
- NP41125: [NP41125 Immunosuppressant Medicines - Find a Tender](#)
- NP43324: [NP43324 HIV Generic Medicines - Find a Tender](#)
- NP47822: [HIV Medicines - Find a Tender](#)
- NP47825: [NP47825 Multiple Sclerosis Medicines - Find a Tender](#)
- NP49425: [NP49425 Generic and Biosimilar Transition Medicines - Find a Tender](#)

Under the [FOISA Section 17 exemption for "Information not held"](#) Public Services Delivery Scotland (PSD Scotland), formerly NHS National Services Scotland (NSS) does not hold supplier-specific total contract values for Teva UK Ltd for these framework agreements.

Question 1: Contract Values for Teva UK Ltd Contracts – Annual spend - The actual spend for the most recent complete financial year (2025/2026, or the nearest 12-month period available).

Whilst PSD Scotland does hold information within the scope of your request, disclosure of this information would, or would be likely to, prejudice substantially the commercial interests of those organisations. Accordingly, PSD Scotland considers this information exempt from disclosure under the [FOISA Section 33\(1\)\(b\) exemption for "Substantial prejudice to commercial interests"](#).

We have considered the public interest in disclosing this information. However, we have concluded that this is outweighed by the public interest in protecting commercially sensitive information and maintaining the confidence of NHS Boards in their engagement with national procurement processes.

You may wish to contact Public Health Scotland or the individual NHSScotland Health Boards listed below, as they may hold the information requested and may consider it appropriate to disclose it:

NHS Ayrshire & Arran – foi@aaaht.scot.nhs.uk
 NHS Borders – foi.enquiries@borders.scot.nhs.uk
 NHS Dumfries & Galloway – dg.feedback2@nhs.scot
 NHS Fife – fife.foirequestfife@nhs.scot
 NHS Forth Valley – fv.freedomofinformation@nhs.scot
 NHS Grampian – gram.foi@nhs.scot
 NHS Greater Glasgow & Clyde – foi@ggc.scot.nhs.uk
 NHS Highland – nhsh.foirequestshighland@nhs.scot
 NHS Lanarkshire – foi@lanarkshire.scot.nhs.uk
 NHS Lothian – foi@nhslothian.scot.nhs.uk
 NHS Orkney – ORK.FOIREquests@nhs.scot
 NHS Shetland – shet.foi@nhs.scot
 NHS Tayside – tay.informationgovernance@nhs.scot
 NHS Western Isles – wi.foi-requests@nhs.scot
 Healthcare Improvement Scotland – His.foi@nhs.scot
 NHS 24 – FOI@nhs24.scot.nhs.uk
 NHS Education for Scotland – nes.foi@nhs.scot

NHS Golden Jubilee – FOI@nwtc.scot.nhs.uk
Public Health Scotland – Phs.foi@phs.scot
Scottish Ambulance Service – [Make a FOI Request](#)
The State Hospital – TSH.FOI-Mailbox@nhs.scot

Question 2: Application of SPPN 3/2026

Please confirm:

a) Has Scottish Procurement Policy Note 3/2026 – Public procurement: human rights and grave professional misconduct – been applied to any supplier by PSD Scotland (or its predecessor NHS National Services Scotland) since its publication in March 2026?

No, since its publication, Scottish Procurement Policy Note (SPPN) 3/2026 has not been applied by PSD Scotland, or its predecessor NHS NSS, to exclude any supplier or to take formal action against them.

SPPN 3/2026 provides guidance to contracting authorities on the options available where there is evidence that a bidder or supplier may have engaged in conduct amounting to grave professional misconduct. Decisions on whether, and how to apply this guidance are made on a case-by-case basis, taking into account the specific circumstances, the available evidence, and the requirements of the relevant procurement legislation.

b) If yes, please identify:

- **The supplier(s) in question**
- **The nature of the alleged misconduct**
- **The outcome of the review (including any contract suspension, termination, or remedial action required)**

Not Applicable, please see the above answer to question 2 (a).

c) If no, please state so explicitly.

No, since its publication, SPPN 3/2026 has not been applied by PSD Scotland, or its predecessor NHS NSS, to exclude any supplier or to take formal action against them.

Question 3: Assessment of Teva UK Ltd under SPPN 3/2026

Please confirm:

a) Has any assessment, review, or preliminary inquiry been conducted to determine whether Teva UK Ltd (or its parent company Teva Pharmaceutical Industries Ltd) is in compliance with the ethical standards required by SPPN 3/2026, specifically regarding:

- **Operations in or links to illegal settlements**
- **Any associated human rights impacts**

No, since the publication of SPPN 3/2026, no assessment, review, or preliminary inquiry has been conducted by PSD Scotland, or its predecessor NHS NSS, to determine whether Teva UK Ltd (or its parent company Teva Pharmaceutical Industries Ltd) is in compliance with the ethical standards required by SPPN 3/2026, specifically regarding operations in, or links to illegal settlements or any associated human rights impacts.

b) If yes, please provide a copy of any such assessment, review memorandum, or decision.

Not Applicable, please see the above answer to question 3 (a).

c) If no, please state the reason why no assessment has been conducted, given that PSD Scotland holds multiple contracts with this supplier and SPPN 3/2026 explicitly identifies illegal settlements as grounds for exclusion.

No, since the publication of SPPN 3/2026, neither PSD Scotland, nor its predecessor NHS NSS, has undertaken any assessment, review, or preliminary inquiry in relation to Teva UK Ltd or its parent company.

SPPN 3/2026 does not require routine or proactive monitoring of all suppliers. It is applied on a case-by-case basis where there is credible evidence of potential grave professional misconduct. In the absence of such evidence in relation to Teva, no assessment has been conducted.

Question 4: Mechanism for Triggering a Supplier Review

Please describe the formal mechanism by which:

a) A member of the public; or b) An organisation, may request or trigger a review of a supplier under SPPN 3/2026.

If no such mechanism exists, please state this explicitly and advise whether PSD Scotland intends to create one.

SPPN 3/2026 does not provide a formal mechanism for members of the public or organisations to request or trigger a review of a supplier.

It sets out guidance for contracting authorities on the options available where there is credible evidence that a bidder or supplier may have engaged in conduct amounting to grave professional misconduct. Decisions on whether, and how, to apply this guidance are made on a case-by-case basis, taking into account the specific circumstances, available evidence, and relevant procurement legislation.

While concerns may be raised through general correspondence or complaints processes, such representations do not in themselves initiate a review under SPPN 3/2026. The decision to undertake any assessment remains at the discretion of the contracting authority.

From 1 April 2026, NSS and NHS Education for Scotland (NES) joined to form PSD Scotland, enabling transformation in health, social care, and the wider public sector. More information regarding PSD Scotland can be found at the following URL:

[Public Services Delivery Scotland \(PSD Scotland\)](#)

I trust you will find the information of assistance and if you require any further information, please do not hesitate to contact me using the email address psd.foi@nhs.scot

If you are unhappy with any aspect of how we have dealt with your request, you can make representations to us asking us to review the handling of your request. Please write to the Associate Director Corporate Governance using the email address psd.foi@nhs.scot within 40 working days of the date of this correspondence.

If after a review you are still unhappy, you also have the right to apply to the Scottish Information Commissioner, who can be contacted at Kinburn Castle, St Andrews, Fife, KY16 9DS, or via their [online Appeal form](#).

Yours sincerely,

A solid black rectangular box redacting the signature of the sender.A solid black rectangular box redacting the name of the sender.